View Older Stories View More Recent Stories

Feb 16, 2022 06:59AM Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reducti
Feb 15, 2022 04:39PM Bristol-Myers Squibb (BMY) Prices $6B Worth of Senior Unsecured Notes
Feb 15, 2022 04:39PM Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
Feb 15, 2022 09:05AM Bristol-Myers Squibb (BMY) Announces Tender Offers for an Aggregate Purchase Price of Up to $4B
Feb 15, 2022 09:04AM Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
Feb 14, 2022 05:02PM Bristol-Myers Squibb (BMY) and Exelisis (EXEL) Report that Opdivo in Combination with CABOMETYX Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial
Feb 14, 2022 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal C
Feb 9, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces $5 Billion Aggregate Accelerated Share Repurchase Agreements
Feb 9, 2022 06:59AM Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
Feb 8, 2022 06:59AM Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
Feb 4, 2022 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
Jan 28, 2022 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for R/R DLBCL, PMBCL and FL3B
Jan 28, 2022 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Jan 11, 2022 02:00AM Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
Jan 11, 2022 02:00AM Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
Jan 10, 2022 08:00AM ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors
Jan 10, 2022 06:59AM Century Therapeutics (IPSC) and Bristol Myers Squibb (BMY) Announce Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
Jan 10, 2022 06:59AM Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
Jan 10, 2022 06:59AM Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
Jan 10, 2022 06:46AM Bristol-Myers Squibb (BMY) Provides 2022 Total Revenue and Non-GAAP EPS Guidance, Announces $5 Billion Accelerated Share Repurchase
Jan 10, 2022 06:45AM Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
Jan 5, 2022 09:03AM Bristol Myers Squibb Selects ZS To Support Global Commercialization and Analytics Capabilities
Jan 4, 2022 06:59AM Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
Dec 17, 2021 06:59AM Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
Dec 15, 2021 03:13PM U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
Dec 15, 2021 08:00AM Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
Dec 14, 2021 07:00AM Immatics (IMTX), Bristol Myers Squibb (BMY) Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Dec 14, 2021 06:59AM Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Dec 14, 2021 06:59AM Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Dec 13, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces Dividend Increase, Additional $15 Billion Share Repurchase
Dec 13, 2021 06:59AM Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
Dec 13, 2021 05:25AM Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM
Dec 11, 2021 08:30AM Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymph
Dec 3, 2021 06:59AM Bristol-Myers Squibb (BMY) Granted FDA Priority Review for BLA for Reblozyl
Dec 3, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalasse
Nov 29, 2021 07:00AM Bristol-Myers Squibb (BMY) Applications for Deucravacitinib for Treatment of Moderate to Severe Plaque Psoriasis Accepted by FDA and Validated by EMA
Nov 29, 2021 06:59AM Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Age
Nov 23, 2021 07:00AM Bristol-Myers Squibb (BMY) Receives European Commission Approval of Zeposia for use in Adults with Moderately to Severely Active UC
Nov 23, 2021 06:59AM Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
Nov 19, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces New April PDUFA Date for Mavacamten
Nov 19, 2021 06:59AM Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
Nov 18, 2021 06:59AM Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
Nov 15, 2021 11:18AM Bristol-Myers Squibb (BMY) Announces Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Nov 15, 2021 11:18AM Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Nov 15, 2021 07:00AM Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease
Nov 10, 2021 06:59AM Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
Nov 10, 2021 02:00AM Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
Nov 8, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces Neoadjuvant Opdivo Plus Chemotherapy Significantly Improves EFS in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Nov 8, 2021 06:59AM Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Nov 8, 2021 06:59AM Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
View More Recent Stories View Older Stories